



# Ovarian Cancer Midwest Focus Virtual Conference

**November 5 - 6, 2020**

The 2020 Ovarian Cancer Midwest Focus (OCMF) Conference will focus on basic science, translational and clinical topics on ovarian cancer, and will offer sessions on emerging topics including Early Detection, Immunotherapy, Novel Therapeutics, Metabolism, Preclinical Models of Ovarian Cancer, Personalized Medicine, Microenvironment, Epigenetics, PARP Inhibitors, Chemoresistance, Combination Therapy, Clinical Studies, Technology Commercialization, and Career Development (virtual lunch and learn).

**Program Chairs:**

Martina Bazzaro, PhD - University of Minnesota-Twin Cities Campus

Ilana Chefetz, PhD - The Hormel Institute, University of Minnesota

Melissa Geller, MD, MS - University of Minnesota-Twin Cities Campus

**Thursday, November 5, 2020**

**Welcome and Opening Remarks - Dr. Melissa Geller**

**Moderator: Dr. Melissa Geller**

8:00 - 8:40 am      Organoids to model human disease  
Hans Clevers, MD, PhD - Hubrecht Institute for Developmental Biology and Stem Cell Research

8:40 - 9:20 am      Ovarian cancer prevention and early detection  
Douglas Levine, MD, FACOG, FACS - New York University Langone

9:20 -10:00 am      Molecular Assessment of Circulating Extracellular Vesicles Towards Liquid Biopsy Diagnosis and Early Detection of Ovarian Cancer  
Andrew Godwin, PhD - University of Kansas Medical Center

10:00 - 11:00 am      Abstract Presentations

- 1) "Macrophage inhibitory factor, osteopontin and prolactin add value to CA-125 as biomarkers for early detection of ovarian cancer"

Presented by Christopher Walker, MD - Detroit Medical Center/Wayne State University

- 2) "Identification of candidate ovarian cancer protein biomarkers in liquid-based Pap tests by mass spectrometry-based proteomics"  
Presented by Amy Skubitz, PhD - University of Minnesota
- 3) "Evaluation of adaptive NK cells in ovarian cancer patients with Cytomegalovirus (CMV) reactivation and systemic inflammation"  
Presented by Erin Wesley, PhD - University of Minnesota
- 4) "Integrated Germline Analysis of Ovarian Cancer Patients Promotes Personalized Medical Care"  
Presented by Andrew Nelson MD, PhD - University of Minnesota

11:00 - 11:40 am Treatment of Advanced Ovarian Cancer Using Gene-edited NK CAR cells  
Timothy Starr, PhD - University of Minnesota

11:40 - 12:00 pm **Break**

**Moderator: Dr. Martina Bazzaro**

12:00 - 12:30 pm	<b>Lunch and Learn</b> Navigating Career Development and Sustainment in Ovarian Cancer Research Patricia Modrow, PhD - Department of Defense
12:30 - 1:00 pm	<b>Lunch and Learn</b> Translation of Investigator-initiated Clinical Trial Deepa Kolaseri, PhD, CCRP - University of Minnesota
1:00 - 1:40 pm	LRRC15 is a novel promoter of ovarian cancer metastatic dissemination Viji Shridhar, PhD - Mayo Clinic
1:40 - 2:00 pm	Achieving Health Equity in Ovarian Cancer: The Role of DEI and Research Ana Núñez, MD, FACP - University of Minnesota
2:00 - 2:20 pm	Ovary and Brain Martina Bazzaro, PhD - University of Minnesota
2:20 - 2:30 pm	<b>Break</b>
2:30 - 3:10 pm	Effect of the germline P72R polymorphism on the mutant TP53 allele selection in human cancer Jeremy Chien, PhD - University of California, Davis
3:10 - 3:50 pm	Precision Medicine Opportunities for Endometrioid Ovarian Carcinoma: Lessons from Endometrial Cancer Michael Anglesio, PhD - University of British Columbia
3:50 - 4:30 pm	Mechanisms of ovarian cancer metastasis to the omentum. Ernst Lengyel, MD, PhD - University of Chicago

**Moderator: Dr. Ilana Chefetz**

8:00 - 8:40 am	Overcoming platinum resistance in ovarian carcinoma Paola Perego, PhD - National Tumor Institute of Milan, Italy
8:40 - 9:20 am	Tumor Heterogeneity Ilana Chefetz, PhD - The Hormel Institute, University of Minnesota
9:20 - 10:00 am	PARP inhibitor response in PDX models: beyond HRD John Weroha, MD, PhD - Mayo Clinic
10:00 - 11:00 am	Abstract Presentations 1) "ARID1A as a possible biomarker of metabolic weak point in Ovarian Clear Cell Carcinoma" Presented by Valentino Clemente, MD - University of Minnesota
	2) "Adipocyte induced pseudohypoxia in ovarian cancer cells regulate metabolism and metastasis" Presented by Abir Mukherjee, PhD - University of Chicago
	3) "Chemotherapy resistance pathways identified by single cell RNA sequencing of sequential ovarian cancer tumor biopsies" Presented by Timothy Starr, PhD - University of Minnesota
	4) "Immune Microenvironment in Endometrioid Ovarian Carcinomas is influenced by Molecular Subtype" Presented by Karolin Heinze, PhD - University of British Columbia
11:00 - 11:40 am	Mesenchymal stem cells are a TME lynch pin driving tumor immune suppression Ron Buckanovich, MD, PhD - Magee-Womens Research Institute
11:40 - 12:00 pm	<b>Break</b>

**Moderator: Dr. Martina Bazzaro**

12:00 - 12:20 pm	<b>Lunch and Learn</b> How to treat ovarian cancer and clinical trials in Japan Akimasa Takahashi, MD, PhD - Shiga University, Japan
12:20 - 12:45 pm	<b>Lunch and Learn</b> with a Message from Our Sponsors
12:45 - 12:55 pm	<b>Break</b>

**Moderator: Dr. Ilana Chefetz**

12:55 - 2:10 pm

### Abstract Presentations

- 1) "Interim Analysis of Cancer Stem Cell Chemotherapeutic Assay for the Treatment of Recurrent Ovarian Cancer: A Randomized Trial"  
Presented by Pier Paolo Claudio, MD, PhD - University of Mississippi
- 2) "Chondroitin Sulfate Proteoglycan 4 (CSPG4), a Targetable Progression-Promoting Tumor Cell Surface Biomarker in Epithelial Ovarian Carcinoma"  
Presented by James McCarthy, PhD - University of Minnesota
- 3) "ALDH1A inhibition as adjuvant to ovarian cancer immunotherapy"  
Presented by Mainpal Rana, PhD - University of Pittsburgh
- 4) "Exploring the role of PDE10 inhibition in ovarian cancer carcinogenesis in the egg-laying hen using RNA sequencing"  
Presented by Annelise Wilhite, MD - University of South Alabama
- 5) "A Ticket to Ride: The Implications of Direct Intercellular Communication via Tunneling Nanotubes in Ovarian and Other Invasive Peritoneal Malignancies"  
Presented by Emil Lou, MD, PhD, FACP - University of Minnesota

2:10 - 3:00 pm      Early tubal precursors lead to nervous tumors  
Ronny Drapkin, MD, PhD - University of Pennsylvania

3:00 - 4:00 pm      Drug resistance in ovarian cancer  
Scott Kaufmann, MD, PhD - Mayo Clinic

### Closing Remarks - Dr. Ilana Chefetz

*Thank You for attending the Ovarian Cancer Midwest Focus Conference*

### Acknowledgement of Support

We gratefully acknowledge the following organizations for their financial contributions to this conference.

Sponsors Include:

**Genentech**

*A Member of the Roche Group*

**CLOVIS ONCOLOGY**

